Enterprise Value

250M

Cash

303.6M

Avg Qtr Burn

-48.15M

Short % of Float

2.17%

Insider Ownership

1.10%

Institutional Own.

64.53%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Rezpegaldesleukin (NKTR-358) Details
Autoimmune disease, Atopic dermatitis

Phase 2b

Data readout

Rezpegaldesleukin (NKTR-358) Details
Autoimmune disease, Alopecia areata

Phase 2b

Data readout

NKTR-255 + Avelumab Details
Urothelial carcinoma, Cancer

Phase 2

Data readout

NKTR-255 (IL-15R agonist) + Cetuximab (Erbitux) (EGFR inhibitor) Details
Head and neck squamous cell carcinoma, Colorectal cancer , Head and neck cancer, Cancer

Phase 1/2

Data readout

NKTR-255 (IL-15 agonist) +/- Daratumumab Details
Multiple myeloma, Non-Hodgkin lymphoma, Cancer

Phase 1/2

Data readout

NKTR-255 (IL-15 agonist) + C-TIL051 Details
Cancer, Non-small cell lung carcinoma

Phase 1

Data readout

Rezpegaldesleukin (LY3471851) (NKTR-358) Details
Autoimmune disease, Systemic lupus erythematosus

Failed

Discontinued

Bempegaldesleukin (NK-214) + VB10.NEO Details
Head and neck squamous cell carcinoma, Cancer

Failed

Discontinued

NKTR-358 Details
Autoimmune disease, Ulcerative colitis

Failed

Discontinued

Bempegaldesleukin (NKTR-214)+ OPDIVO (Nivolumab) Details
Urothelial cancer, Cancer, Bladder cancer

Failed

Discontinued

Dapirolizumab Pegol (anti-CD40L) Details
Systemic lupus erythematosus, Autoimmune disease

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Onzeald (etirinotecan pegol) Details
Metastatic breast cancer to brain, Cancer

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued